- New York-based Solstice raised $21M in Series A funding led by Transformation Capital, bringing total funding to nearly $25M
- The startup uses AI to reduce pharma marketing and regulatory review timelines from months to under 10 days
- Solstice already works with over a dozen pharmaceutical companies, including several top 20 global pharma brands
The healthcare and pharmaceutical industry spends more than $100 billion annually on commercialisation and marketing efforts. Yet despite rapid advances in AI across healthcare, pharma marketing workflows remain heavily manual, fragmented, and dependent on lengthy medical, legal, and regulatory (MLR) review cycles. In many cases, even routine assets such as physician emails or patient communications can take three months to gain approval.
Solstice says its AI-native platform reduces that timeline dramatically, enabling pharmaceutical brands to move from content creation to MLR submission in under 48 hours and launch campaigns in roughly 10 days.
The New York-based startup has raised $21 million in a Series A round led by Transformation Capital to accelerate how pharmaceutical companies create and approve compliant marketing content using AI. Existing investors including Twelve Below and Virtue Ventures also participated in the round, bringing the company’s total funding to approximately $25 million.
Why pharma marketing remains painfully slow
Launching a new therapy is one of the most time-sensitive processes in healthcare. Pharmaceutical companies operate under shrinking patent exclusivity windows, where delays in commercialisation can directly affect revenue generation and patient access to treatment.
Traditionally, pharma marketing involves multiple disconnected teams, including agencies, compliance departments, legal reviewers, medical experts, and internal marketers. Each marketing asset often undergoes several rounds of revisions before approval. The result is a costly bottleneck that slows product launches and limits the ability of brands to personalise communication for physicians and patients.
Founded to unify content generation, compliance, and performance insights
Solstice was founded by Yiwen Li and Aris Saxena in New York and was publicly launched in 2025 to solve the operational inefficiencies slowing pharmaceutical commercialisation. The company combines proprietary pharmaceutical marketing AI models with in-house compliance and subject-matter experts to generate and review marketing content at scale.
Its platform ingests clinical data, FDA documents, approved literature, and brand guidelines to build a grounded understanding of a pharmaceutical product. It can then automatically generate compliant digital campaigns, physician communications, patient engagement assets, and programmatic advertisements.
Unlike general-purpose AI tools, Solstice is specifically designed around the regulatory complexity of pharmaceutical marketing.
According to the company, every generated asset is evaluated for its likelihood of passing MLR review before it even reaches regulatory teams. Solstice also predicts which marketing assets are most likely to drive physician and patient engagement, helping brands optimise campaign performance.
“We built Solstice to help life sciences teams bring therapies to market faster with one AI-native system,” said Saxena. “Customers now need only one or two review cycles, and campaigns launch in about 10 days.”
Why investors are betting on AI infrastructure for pharma commercialisation
Healthcare investors increasingly see pharmaceutical commercialisation as one of the largest untapped AI opportunities in the industry. The AI pharma commercialisation market is becoming increasingly competitive as investors pour capital into platforms modernising pharmaceutical marketing and compliance workflows.
Enterprise MLR automation giant Veeva Systems dominates the legacy content review infrastructure through its Vault PromoMats platform, which Solstice directly targets with its AI-native alternative. Meanwhile, full-service commercialisation platform EVERSANA launched EVERSANA ORCHESTRATE MLR, an AI-powered tool that identifies, extracts, and manages regulatory claims in minutes, promising 90% faster updates and 50% fewer submission errors across its agency client base.
New York-based Klick Health, one of the largest independent health agencies, has been aggressively integrating AI into its MLR and content workflows, while Inizio Evoke is scaling generative AI tools across pharma marketing operations to accelerate speed to market for pharmaceutical brands.
Solstice differentiates itself by focusing specifically on pharmaceutical commercialisation and MLR review workflows, an area that still depends heavily on agencies, fragmented approval systems, and manual compliance processes. Unlike competitors focused primarily on research, diagnostics, or clinical development, Solstice is positioning itself as an infrastructure for compliant pharma marketing operations. Its platform combines proprietary pharmaceutical marketing models with in-house regulatory, medical, and creative expertise to accelerate the production and approval of marketing assets.
The startup claims its customers are now launching marketing campaigns 12 times faster compared to traditional agency workflows. The company’s ability to move campaigns from concept to MLR submission in under 48 hours, while reducing review cycles from 3.2 rounds to 1.2 rounds, positions Solstice within a growing category of vertical AI systems designed for highly regulated enterprise environments.
The platform is already being used by more than a dozen pharmaceutical companies, including several top 20 global pharma brands across oncology, immunology, and metabolic disease markets.
“Biopharma commercialisation is one of the largest and most regulated workflows in healthcare, and it has been running on a model built long before AI could change it,” said Vinay Shah, partner and founding team member at Transformation Capital. “The team at Solstice has the technical depth to solve real compliance problems and the operational judgment to sell into one of the most demanding buyer environments in healthcare.”
The bigger picture
The company plans to use the new funding to expand go-to-market operations, accelerate product development, and grow engineering and customer-facing teams.
While much of the healthcare AI investment boom has focused on drug discovery and clinical research, Solstice represents a growing category of startups targeting the operational side of pharmaceutical companies.
The question is whether AI-native platforms like Solstice can fully replace the deeply entrenched agency and regulatory workflows that have dominated pharma marketing for decades or whether human oversight will continue to limit the speed gains AI promises.
